Understanding the Market | CT ENTERPRISE rose over 8% again as Muyuan Group and Charoen Pokphand Group reached a strategic cooperation. The company is a producer of gold powder under Charoen Pokphand
CT ENTERPRISE rose more than 8% again, with a cumulative increase of over 570% this year. As of the time of writing, it rose 8.79% to HKD 10.02, with a transaction volume of HKD 15.4734 million. In terms of news, on August 28, Muyuan Group and Charoen Pokphand Group officially signed a strategic cooperation agreement at the True Building in Bangkok, Thailand. This collaboration, seen as a partnership between the world's first and third largest pig farming giants, will involve comprehensive cooperation in areas such as strategic planning, business integration, and global layout, promoting deep collaboration in feed, pig farming, slaughtering and food processing, talent, and capital. Public information shows that CT ENTERPRISE is a subsidiary of Charoen Pokphand Group and is one of the world's leading producers of chlortetracycline. Huaxin Securities previously pointed out in a research report that looking at the global veterinary chlortetracycline market, China's Jinhe Biological and Charoen Pokphand Biological together account for over 90% of global production capacity, presenting a duopoly competition pattern. Financial reports show that the company's net profit in the first half of the year increased by 768.36% year-on-year, mainly due to the significant growth of the group's biochemical business, which focuses on animal health pharmaceutical products and chlortetracycline
According to Zhitong Finance APP, CT ENTERPRISE (03839) has risen over 8% again, with a cumulative increase of over 570% this year. As of the time of writing, it has risen by 8.79%, priced at HKD 10.02, with a transaction volume of HKD 15.4734 million.
On the news front, on August 28, Muyuan Group and Charoen Pokphand Group officially signed a strategic cooperation agreement at the True Building in Bangkok, Thailand. This collaboration, seen as a partnership between the world's first and third largest pig farming giants, will involve comprehensive cooperation in areas such as strategic planning, business integration, and global layout, promoting deep collaboration in feed, pig farming, slaughtering and food processing, talent, and capital.
Public information shows that CT ENTERPRISE is a subsidiary of Charoen Pokphand Group and is one of the world's leading producers of oxytetracycline. Huaxin Securities previously pointed out in a research report that in the global veterinary oxytetracycline market, China's Jinhe Biological and Charoen Pokphand Biological together account for over 90% of global production capacity, presenting a duopoly competitive landscape. Financial reports indicate that the company's net profit in the first half of the year increased by 768.36% year-on-year, mainly due to significant growth in the group's biochemical business, which focuses on animal health chemical products and oxytetracycline
